You are here: Industry Insights > Parkinson

News List

Cash-strapped Titan delays Parkinson’s implant program fiercebiotech
July 09, 2018
Titan Pharmaceuticals has been cleared to start the second phase of a trial of its ropinirole implant for Parkinson’s disease—but will have to postpone it because of financial constraints.
Promising new drug slows Parkinson's progression in mice pharmafile
July 06, 2018
According to investigators of the study, which has been published in the journal Nature Medicine, the compound prevents the process through which astrocytes – star shaped cells that assist neurons in communicating – are converted into aggressive ‘activat
Axovant buys rights for Oxford BioMedica’s Parkinson’s candidate pharmatimes
June 13, 2018
Biopharmaceutical firm Axovant Sciences has agreed exclusive worldwide rights for the development and commercialisation of gene therapy company Oxford BioMedica’s investigational candidate OXB-102, now known as AXO-Lenti-PD, for the treatment of Parkinson
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease biospace
April 24, 2018
PMDAlliance and Acadian Pharmaceuticals today announced the results of a survey on the effects of non-motor symptoms in patients with Parkinson's disease (PD)
Acadia shares hit by media doubts over Parkinson’s drug pharmaphorum
April 12, 2018
Shares in US biotech Acadia have fallen sharply following a news story linking its Parkinson’s drug Nuplazid with patient deaths.
Media reports over Parkinson’s drug risk hit Acadia hard pharmafile
April 11, 2018
The death toll from taking Acadia Pharmaceutical company Nuplazid, the stock price of this biotechnology company dropped from 35 to 27 in just a few weeks
Lundbeck takes risk on Parkinson’s treatment, €905m on table pharmafile
March 20, 2018
CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take a calculated risk on Prexton Therapeutics and its sole candidate for Parkinson’s.
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of i worldpharmanews
March 19, 2018
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton
Voyager Therapeutic's Parkinson's Trial Shows Positive Results biospace
March 12, 2018
Voyager Therapeutics, headquartered in Cambridge, Massachusetts, released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease.
Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs biospace
March 09, 2018
Seven months after Prevail Therapeutics launched the New York-based company has secured $75 million in Series A financing to support the development of gene therapies

Previous page 1 2 3 4 5 6 7 8 9 Next page